Craft

Biosynex

Stock Price

€3

2024-10-29

Market Capitalization

€33.1 M

2024-10-29

Revenue

€101.2 M

FY, 2024

Biosynex Summary

Company Summary

Overview
BIOSYNEX, founded in 2005, together with BIOSYNEX Germany (previously DIMA GmbH), founded in 1996, are members of the BIOSYNEX Group. The BIOSYNEX Group is one of the most significant European manufacturers and provider of rapid membrane tests in the in-vitro diagnostic market. By staying close to our customers and business partners we are aware of the needs and expectations they may have of our products and services. Listening to their voice, together with the help of our Research and Development laboratories in Germany and France and our state of the art manufacturing facilities, allows us to identify new applications in rapid testing, develop and launch innovative products and provide high quality services. We offer high quality, easy to use Drugs of Abuse, Infectious Disease, Obstetric, Virology, Bacteriology, Autoimmune Disease, Oncology and Parasitology kits. Our aim is to provide innovative diagnostic tests to help physicians make fast and better medical and therefore lifesaving decisions.
Type
Public
Status
Active
Founded
2005
HQ
Illkirch-Graffenstaden, FR | view all locations
Website
http://www.biosynex.com/en/
Cybersecurity rating
Sectors

LocationsView all

1 location detected

  • Illkirch-Graffenstaden, Grand Est HQ

    France

    22 Bd Sébastien Brant

Biosynex Financials

Summary Financials

Revenue (H1, 2025)
€50.5M
Gross profit (H1, 2025)
€34.0M
Net income (H1, 2025)
(€48.4M)
Cash (H1, 2025)
€4.8M
EBIT (H1, 2025)
(€46.2M)
Enterprise value
$90.4M

Footer menu